CYSTIC FIBROSIS

Improving rate of decline of FEV₁ in young adults with cystic fibrosis

C Que, P Cullinan, D Geddes

Thorax 2006;61:155-157. doi: 10.1136/thx.2005.043372

See end of article for authors' affiliations

Correspondence to: Professor D Geddes, Respiratory Medicine, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK; d.geddes@rbh.nthames.nhs.uk

Received 2 March 2005

Accepted

21 November 2005

Published Online First
29 December 2005

Background: CF is characterised by a progressive decline in lung function; reductions in this decline are often used as a measure of success in clinical trials. With improvements in treatment it may be that there has been a temporal shift in the pattern of the disease.

Methods: 318 patients born in five successive cohorts and attending a specialist clinic with at least two routine measurements of lung function made between the ages of 18 and 22 were included. The declines in their lung function were estimated and compared.

Results: The mean (SE) slopes for percentage predicted forced expiratory volume in 1 second (FEV₁) and forced vital capacity (FVC) were -1.53 (0.36)% and -1.27 (0.34)%, respectively (NS). The annual deterioration in FEV₁ was -2.49%, -1.99% -2.20%, -1.65%, and -0.65% from the earliest to the most recent birth cohort; a similar pattern was observed for changes in FVC. There were no differences between male and female patients. Patients infected with *Pseudomonas* had a greater average decline in FEV₁ (-1.6% v -1.1%).

Conclusions: The rates of decline in lung function in young adults with CF have diminished with successive birth cohorts. This has important implications for the design of clinical studies in this disease.

Cystic fibrosis (CF) is a progressive condition in which pulmonary disease is the main determinant of morbidity and mortality. The progressive decline in pulmonary function with time has been a feature of CF lung disease in the past and seems to be inevitable in all patients. The annual rate of decline in forced expiratory volume in 1 second (FEV₁) percentage predicted is a significant predictor of the risk of death,¹ and the annual deterioration in FEV₁ percentage predicted is considered a better parameter than single measurements for referral for lung transplantation.^{2,3} The mean rates of FEV₁ decline reported in the literature are shown in table 1.

In clinical trials, based on the assumption that CF causes a progressive decline in lung function, a reduction in this decline during the observation period is a common outcome measure.⁴⁻⁶ With improvements in treatment it may be that the pattern of CF pulmonary disease is not the same today as it was in the past. We set out to determine the rate of lung function change in a contemporary cohort of young adults

with CF and to compare this with rates in earlier birth cohorts.

METHODS

Population

The adult CF service at Royal Brompton Hospital cares for all patients aged 16 years or over, currently some 700. These are seen regularly in clinic and, since 1981, have undergone formal annual review with full lung function testing. Using attendance records of the last 10 years from the hospital lung function laboratory, we identified all adult CF patients (>18 years). 318 patients with at least two pulmonary function tests (in two calendar years) between the ages of 18 and 22 form the study base for this analysis. Tests dated from as early as 1978 to the end of 2004. The highest prebronchodilator FEV₁ and forced vital capacity (FVC) were used to calculate the rates of changes. Information was also collected on year of birth, sex, height at ages 18 and 22 years, and chronic *Pseudomonas* infection (defined as *Pseudomonas*

Table 1 Published rates of decline in percentage predicted FEV₁ in cystic fibrosis

Reference	No of patients	Age (years)	Follow up (years)	Annual decline in FEV ₁ % predicted	
				Mean	SE
Corey ⁷	132	5-27	7	-1.87 (male) -2.71 (female)	NS*
Kerem ⁸	39	7-40	2	-2.2	1.67
Kovesi ⁹	325	4-28	15	-1.25	0.14
Konstan ⁵	43	5-39	4	-3.6	0.55
Eigen ¹⁰	95	6-14	4	-1.5	NS
Corey ¹¹	366	18-32	15	-2.72	NS
Davis ⁴	215		2-5	-2.3	0.28
Millar ¹²	152		4	-2.44	NS
Merkus ¹³	52	Children	3.9	-2.2	NS
Merkus ¹⁴	53	Children	3.8	-1.8	NS

*Not stated.

Table 2 Mean height, pulmonary function, and FEV₁ slope (percentage predicted) from age 18 to 22 years by birth cohort

	Birth cohort				
	1960–4	1965–9	1970–4	1975–9	1980–4
Patients (n)	17	28	62	113	98
Measurements (n)	40	76	167	349	314
Mean height at age 18 (cm)	n/a	n/a	167.1	167.2	167.4
Mean FEV ₁ at 22 years (%)	45.96%	59.75%	53.47%	56.77%	63.68%
FEV ₁ % predicted slope	–2.49%	–1.99%	–2.2%	–1.65%	–0.65%
Mean FVC at 22 years (%)	68.13%	78.02%	69.85%	75.18%	81.8%
FVC % predicted slope	–2.1%	–1.35%	–1.86%	–1.34%	–0.64%

Figure 1 Mean (SE) changes in percentage predicted FEV₁ by birth cohort (numbers 1–5 refer to birth cohorts 1960–4, 1965–9, 1970–4, 1975–9, and 1980–4). **Figure 2** Mean (SE) changes in percentage predicted FVC by birth cohort (numbers 1–5 refer to birth cohorts 1960–4, 1965–9, 1970–4, 1975–9, and 1980–4).

aeruginosa cultured in at least three consecutive sputum samples at least 1 month apart during the study period).

Statistical analysis

Percentage predicted values of FEV₁ and FVC were calculated using the European community reference population. Annual changes in lung function were estimated using linear regression analysis. Lung function changes were distributed approximately normally and are expressed as mean (SE). We analysed time trends after categorising patients into successive 5 year birth cohorts and fitting “cohort” as a variable in a

linear regression model; differences between cohorts were assessed using ANOVA.

RESULTS

Between the ages of 18 and 22 years the mean (SE) annual changes in percentage predicted FEV₁ and FVC among all patients were –1.53 (0.36)% and –1.27 (0.34)%. The rates of change tended to be greater in the earlier birth cohorts (table 2), but the trends were not statistically different ($p = 0.28$ and $p = 0.35$ for FEV₁ and FVC, respectively). The trends were clearer, but again statistically not significant among patients born only after 1970 (figs 1 and 2).

There were fewer than 20 patients of either sex in the earlier two cohorts, so time trends by sex were analysed using only the later three cohorts. Among men born after 1970, the mean changes in FEV₁ percentage predicted were –1.57% (1970–4 cohort), –0.57% (1975–9), and –0.91% (1980–4). These differences were not statistically significant ($p = 0.66$). Among women born within the same cohorts, the estimated changes in FEV₁ percentage predicted were –2.48%, –2.98%, and –0.29%, respectively ($p = 0.69$).

There were no important differences between the different cohorts in mean height at age 18 (table 2) or 22 years (data not shown). Forty nine patients (15.4%) had no evidence of chronic *P aeruginosa* colonisation over the period of the study. Among these, the mean (SE) annual decline in FEV₁ percentage predicted was –1.1 (0.8)%; patients infected with *Pseudomonas* had a higher mean decline (–1.61 (0.41)%). This difference was not statistically significant.

DISCUSSION

Our findings indicate that the annual rate of decline in lung function among contemporary young adults with CF is very low, and is lower than among previous generations of adults with the disease. While it is possible that these apparent improvements occurred by chance, they are consistent with improvements in CF care and prognosis over the past 30 years.

There are several possible biases in our findings. Patients were selected on the basis of their having had lung function measurements at any age between 1995 and 2004, and we subsequently examined those measurements made when these patients were aged between 18 and 22 years. Patients

Table 3 Lung function decline in children with cystic fibrosis¹⁹

	Birth cohort					
	1960–4	1965–9	1970–4	1975–80	1980–4	1985–9
Follow up to	1978	1983	1988	1993	1998	2003
Study (n)	132	120	114	90	90	108
FEV ₁ slope	–2.1	–2.6	–2.5	–1.8	–1.1	–0.8

were therefore selected by their survival and may have relatively mild disease. We suggest that this is likely to have resulted in an underestimate of the true rates of lung function decline in earlier cohorts and thus an underestimate of the true temporal differences. Furthermore, we cannot be sure that the indications for annual lung function testing remained the same throughout the period of our analysis. Analysis of the later three cohorts, all born after the period when routine testing was practised and in whom survival pressures are probably less marked, tended to confirm our overall findings.

The annual fall in FEV₁ percentage predicted is believed to be associated with genotype, sex, pancreatic and nutritional status, and colonisation with mucoid strains of *P aeruginosa*.^{11 15 16} We were unable to show a difference between male and female patients in FEV₁ decline; while this may be due to small numbers, similar findings have been reported in Swedish patients.¹⁷ Nor did we find any important difference in terms of height, which might be associated with nutritional status. We did not examine the effects of weight, but one study has suggested that children with CF who weigh more and who gain weight at an appropriate and uninterrupted rate have a better FEV₁ trajectory.⁶ Our result with regard to the effect of *P aeruginosa* colonisation/infection on lung function decline is consistent with that of Schaedel *et al.*¹⁷ We were unable to demonstrate a statistically significant association between this and lung function decline, possibly because of the small number of non-colonised patients. We did not identify the time at which the patients acquired *Pseudomonas* and cannot separate cause from effect as others have.¹⁸

Our results are similar to those of children in Toronto summarised in table 3,¹⁹ and to reports of patients treated with rhDNase.²⁰ They are consistent with improving trends in survival and probably reflect better standards of care organised within specialist CF centres, and more aggressive approaches to treatment, especially with nebulised antibiotics and DNase. An important implication is that decline in lung function may now be too insensitive a measure for use in clinical trials of limited periods.

In conclusion, the rate of decline of FEV₁ in patients with CF is falling, in line with improved survival, and is now approaching zero. This is probably due to improved treatment. There are major implications for the future design of clinical trials.

Authors' affiliations

C Que, P Cullinan, D Geddes, Department of Respiratory Medicine, Royal Brompton Hospital, London SW3 6NP, UK

Competing interests: none

REFERENCES

- 1 Milla CE, Warwick WJ. Risk of death in cystic fibrosis patients with severely compromised lung function. *Chest* 1998;**113**:1230–4.
- 2 Rosenbluth DB, Wilson K, Ferkol T, *et al.* Lung function decline in cystic fibrosis patients and timing for lung transplantation referral. *Chest* 2004;**126**:412–9.
- 3 Augarten A, Akons H, Aviram M, *et al.* Prediction of mortality and timing of referral for lung transplantation in cystic fibrosis patients. *Pediatr Transplant* 2001;**5**:339–42.
- 4 Davis PB, Byard PJ, Konstan MW. Identifying treatments that halt progression of pulmonary disease in cystic fibrosis. *Pediatr Res* 1997;**41**:161–5.
- 5 Konstan MW, Byard PJ, Hoppel CL, *et al.* Effect of high-dose ibuprofen in patients with cystic fibrosis. *N Engl J Med* 1995;**332**:848–54.
- 6 Ramsey BW, Dorkin HL, Eisenberg JD, *et al.* Efficacy of aerosolized tobramycin in patients with cystic fibrosis. *N Engl J Med* 1993;**328**:1740–6.
- 7 Corey M, Levison H, Crozier D. Five- to seven-year course of pulmonary function in cystic fibrosis. *Am Rev Respir Dis* 1976;**114**:1085–92.
- 8 Kerem E, Corey M, Gold R, *et al.* Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with *Pseudomonas aeruginosa*. *J Pediatr* 1990;**116**:714–9.
- 9 Kovsi T, Corey M, Levison H. Passive smoking and lung function in cystic fibrosis. *Am Rev Respir Dis* 1993;**148**:1266–71.
- 10 Eigen H, Rosenstein B, FitzSimmons S, *et al.* A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. *J Pediatr* 1995;**126**:515–23.
- 11 Corey M, Edwards L, Levison H, *et al.* Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. *J Pediatr* 1997;**131**:809–14.
- 12 Milla CE, Warwick WJ, Moran A. Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. *Am J Respir Crit Care Med* 2000;**162**:891–5.
- 13 Merkus PJ, Tiddens HA, de Jongste JC. Annual lung function changes in young patients with chronic lung disease. *Eur Respir J* 2002;**19**:886–91.
- 14 Merkus PJ, Govaere ES, Hop WH, *et al.* Preserved diffusion capacity in children with cystic fibrosis. *Pediatr Pulmonol* 2004;**37**:56–60.
- 15 Rosenbluth DB, Wilson K, Ferkol T, *et al.* Lung function decline in cystic fibrosis patients and timing for lung transplantation referral. *Chest* 2004;**126**:412–9.
- 16 Augarten A, Akons H, Aviram M, *et al.* Prediction of mortality and timing of referral for lung transplantation in cystic fibrosis patients. *Pediatr Transplant* 2001;**5**:339–42.
- 17 Schaedel C, De Monestrol I, Hjelte L, *et al.* Predictors of deterioration of lung function in cystic fibrosis. *Pediatr Pulmonol* 2002;**33**:483–91.
- 18 Kosorok MR, Zeng L, West SE, *et al.* Acceleration of lung disease in children with cystic fibrosis after *Pseudomonas aeruginosa* acquisition. *Pediatr Pulmonol* 2001;**32**:277–87.
- 19 Xu W, Subbarao P, Corey M. Changing patterns of lung function decline in children with cystic fibrosis. *J Cystic Fibrosis* 2004;**3**:S116.
- 20 Hodson ME, Koch C, Harries HK, *et al.* The European Epidemiologic Registry of Cystic Fibrosis (ERCF). Does dornase alfa make any difference? In: *Proceedings of the 22nd European CF Conference, Berlin, Germany*. Berlin: European CF Conference, 1998:66.